文献速递腹部介入CTMR

多学科背景下肝细胞癌影像学的批判性综述:治疗分配与疗效评估

Critical review of HCC imaging in the multidisciplinary setting: treatment allocation and evaluation of response.
PubMed 文献 · Abdom Radiol (NY) · 2020-01-01

本文综述了影像学在肝细胞癌多学科管理中的作用:BCLC系统依据肿瘤负荷、肝功能和癌症相关症状将患者分为0、A、B、C、D五期以指导治疗选择;疗效评估推荐按mRECIST标准测量存活肿瘤并分类为完全缓解、部分缓解、稳定疾病或进展性疾病,CT或MR均可用于此目的,LI-RADS委员会已提供局部治疗后报告指南。

要点

  • BCLC系统仍是将患者分层至不同治疗选项的最适方法,分为0、A、B、C、D五期。
  • 疗效评估现行指南推荐仅按mRECIST标准测量存活肿瘤,并分类为完全缓解、部分缓解、稳定疾病或进展性疾病。
  • TARE后的治疗相关改变可造成影像陷阱,影响疗效的正确评估。

核心结论

  • 影像学在肝细胞癌患者的筛查、诊断、患者分层、治疗分配及疗效评估中均具有关键作用。
  • BCLC系统仍是将患者分层至最佳治疗候选队列的最适方法,依据肿瘤负荷与范围、肝功能及癌症相关症状分为0、A、B、C、D五期。
  • 目前生物标志物在治疗分配中尚无明确作用。
  • 客观缓解已成为重要的影像生物标志物,可提供肿瘤生物学信息并有助于进一步预后评估。
  • 现行客观缓解评估指南仅推荐按mRECIST标准测量存活肿瘤,并进一步分类为完全缓解、部分缓解、稳定疾病或进展性疾病。

研究设计与样本

  • 本文为综述,讨论肝细胞癌多学科评估中治疗分配的最新决策方面,并为疗效评估提供指导。
  • BCLC系统依据影像信息中的肿瘤负荷与范围、肝功能及癌症相关症状进行分层。
  • CT或MR均可用于按mRECIST标准评估客观缓解。
  • LI-RADS委员会近期已提供局部治疗后的报告指导。

诊断标准与关键数值

  • BCLC系统将患者分为0、A、B、C、D五期,各期对应不同治疗选项。
  • 现行指南推荐按mRECIST标准测量存活肿瘤以评估客观缓解,并分类为完全缓解、部分缓解、稳定疾病或进展性疾病。
  • CT或MR均可用于按mRECIST标准评估疗效。
  • LI-RADS委员会已提供局部治疗后的报告指导。

临床应用与阅片要点

  • 治疗分配中应采用BCLC系统,综合影像上的肿瘤负荷与范围、肝功能及癌症相关症状进行分期。
  • 局部区域非手术治疗在不同分期中的应用日益增多,其疗效评估依赖可靠的存活肿瘤测量,尤其在以治愈为目的或用于肝移植再评估降期时。
  • 按mRECIST标准测量存活肿瘤并分类为完全缓解、部分缓解、稳定疾病或进展性疾病。
  • 需注意治疗相关改变所致的影像陷阱可影响疗效的正确评估,尤其在TARE后。
  • 容量标准和新兴影像技术可能有助于进一步优化疗效评估与监测。

局限性

  • 目前生物标志物在治疗分配中尚无明确作用。
  • 治疗相关改变所致的影像陷阱可影响疗效的正确评估,尤其在TARE后。
  • 容量标准和新兴影像技术可能有助于进一步优化疗效评估与监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Imaging has not only an established role in screening and diagnosis of hepatocellular carcinoma (HCC) in patients with chronic liver inflammatory diseases, but also a crucial importance for patient stratification and treatment allocation, as well as for assessing treatment response. In the setting of increasing therapeutic options for HCC, the Barcelona Clinic Liver Cancer (BCLC) system still remains the most appropriate way to select candidate cohorts for best treatments. This classification takes into account the imaging information on tumor burden and extension, liver function, and cancer-related symptoms, stratifying patients in five risk categories (Stages 0, A, B, C and D) associated with different treatment options. Still now, there are no clear roles for biomarkers use in treatment allocation. The increasing use of locoregional non-surgical therapies in the different stages is highly dependent on reliable evaluation of treatment response, in particular when they are used with curative intention or for downstaging at liver transplantation re-assessment. Moreover, objective response (OR) has emerged as an important imaging biomarker, providing information on tumor biology, which can contribute for further prognostic assessment. Current guidelines for OR assessment recommend only the measurement of viable tumor according to mRECIST criteria, with further classification into complete response, partial response, stable disease or progressive disease. Either computed tomography (CT) or magnetic resonance (MR) imaging can be used for this purpose, and the Liver Imaging Reporting and Data System (LI-RADS) committee has recently provided some guidance for reporting after locoregional therapies. Nevertheless, imaging pitfalls resulting from treatment-related changes can impact with the correct evaluation of treatment response, especially after transarterial radioembolization (TARE). Volume criteria and emerging imaging techniques might also contribute for a better refinement in the assessment of treatment response and monitoring. As the role of imaging deeply expands in the multidisciplinary assessment of HCC, our main objective in this review is to discuss state-of-the-art decision-making aspects for treatment allocation and provide guidance for treatment response evaluation.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Amorim J, França M, Perez-Girbes A, et al. Critical review of HCC imaging in the multidisciplinary setting: treatment allocation and evaluation of response. Abdom Radiol (NY). 2020. PMID: 32173774. doi:10.1007/s00261-020-02470-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。